ICCC Q2 2021 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+53.1% YoY

Gross Profit

$2M45.7% margin

Operating Income

$215,5084.7% margin

Net Income

$141,1133.1% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+10.6%

Cash Flow

Operating Cash Flow

$730,832

Free Cash Flow

-$148,507

Stock-Based Comp.

$23,265

Balance Sheet

Total Assets

$44M

Total Liabilities

$11M

Stockholders' Equity

$32M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$3M	+53.1%
Gross Profit	$2M	$1M	+61.6%
Operating Income	$215,508	-$691,269	+131.2%
Net Income	$141,113	-$765,793	+118.4%

Revenue Segments

FirstDefenseProductLineMember

$4M98%

OtherAnimalHealthMember

$68,8632%

Geographic Segments

UNITED STATES

$4M89%

OtherStatesMember

$511,57311%